Department of Oncology

Clinician and patient attitudes toward locoregional treatment of oligometastatic oesophago-gastric cancers: a mixed-methods study

Lakha AS. et al, (2026), ESMO Gastrointestinal Oncology, 13

Zolbetuximab plus pembrolizumab and chemotherapy in CLDN18.2-positive, HER2-negative, PD-L1-positive gastric or gastroesophageal junction adenocarcinoma: randomized, double-blind, phase III LUCERNA trial

Shitara K. et al, (2026), ESMO Gastrointestinal Oncology, 13

Can GLP-1RA be utilised for pre-operative liver optimisation prior to hepatectomy? A scoping review of MASLD evidence with surgical translation

Vaitha R. et al, (2026), Clinical Surgical Oncology, 5, 100136 - 100136

Nucleophagy as an emerging therapeutic vulnerability in cancer.

Tribble S. and Ramadan K., (2026), Autophagy, 1 - 3

Oncology drug development in the UK: analysis of the past 25 years and focus on the 2026 reboot of the clinical trial regulatory framework.

Czajka-Francuz P. et al, (2026), Br J Cancer

The FAIR Case for A Coherent Interoperability to support NHS 10 Year Health Plan.

Tomlinson H. et al, (2026), Sci Data

Evidence of endothelial anergy and T-cell exclusion in microsatellite stable colorectal liver metastases revealed through human hemi-liver perfusion and spatial transcriptomics.

Wan PK-T. et al, (2026), Mol Cancer

Preclinical characterization and phase 1 clinical testing of targeting mitochondrial peroxiredoxin 3 in cancer.

Gibson V. et al, (2026), Nat Commun, 17

Down-Regulation of Proline Rich Homeodomain/Haematopoietically Expressed Homeobox Expression in Prostate Cells Enables Tumour Initiation and Tumour Growth.

Marcolino E. et al, (2026), Cancers (Basel), 18

The pharmacological profile of ART6043, a first-in-class clinical DNA polymerase theta polymerase domain inhibitor potentiating PARP inhibitor efficacy.

Robinson HMR. et al, (2026), Clin Cancer Res

Benefit of adjuvant chemotherapy for resected pancreatic cancer following neoadjuvant FOLFIRINOX or Gemcitabine-Nab-paclitaxel: a multinational analysis.

Lopez-Lopez V. et al, (2026), J Natl Cancer Inst

Antibody-drug conjugates in selected solid tumours: a position statement update based on findings from the third workshop held by the ETOP IBCSG Partners Foundation.

Peters S. et al, (2026), ESMO Open, 11

Tirapazamine sensitises hypoxic homologous recombination-proficient NSCLC to PARP inhibition.

Jiang Y. et al, (2026), Cell Death Discov

Forging New Pathways in Oncology: Strategic Insights from the 17th Annual Frontiers in Cancer Science Conference.

Huang D. et al, (2026), Cancer Res, 86, 3106 - 3108

CDIN1-Codanin-1 complex defective in congenital dyserythropoietic anaemia type I is an RNA nuclease.

Brolih S. et al, (2026), Nat Commun

Addition of rituximab to first-line treatment of Burkitt lymphoma in children and young adults in Tanzania: a cost-utility analysis

MORRELL L. et al, (2026), Journal of Clinical Oncology Global Oncology

Identification of a Novel GOLGB1-RET Fusion in Papillary Thyroid Cancer With a Durable Response to Selpercatinib.

Boku S. et al, (2026), JCO Precis Oncol, 10

Cell-Free DNA Analysis With Clinicopathologic Factors for Early Detection and Refining Lymph Node Metastasis Risk in T1 Colorectal Cancer: Results From the COSMOS-CRC Study.

Murano T. et al, (2026), JCO Precis Oncol, 10

Diagnostic Implications of Multi-Cancer Early Detection Testing in the Investigation of Cancer Symptoms: An Exploratory Retrospective Analysis of the SYMPLIFY Study.

Jackson A. et al, (2026), Lancet Reg Health Eur, 66

Current status of radionuclide therapy targeting PARP in cancer: challenges and prospects.

Kurniawan A. et al, (2026), Eur J Nucl Med Mol Imaging

Search results

Showing results for